Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

New development in CAR-T cell therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

A long way to the battlefront: CAR T cell therapy against solid cancers.

Current progress in CAR-T cell therapy for tumor treatment

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

The progress of CAR-T therapy in cancer and beyond

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Relapse after CAR-T Cell Therapy in B-cell Malignancies: Challenges and Future Approaches

Current Progress in CAR-T Cell Therapy for Solid Tumors

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Current state of CAR-T therapy for T-cell malignancies

CAR-T cell therapy: current limitations and potential strategies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR T‐cell therapy: Full speed ahead